Old Web
English
Sign In
Acemap
>
authorDetail
>
Ruby Nandam
Ruby Nandam
AbbVie
Rituximab
Venetoclax
Medicine
Drug
Immunology
3
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
2021
Blood
Shuo Ma
John F. Seymour
Danielle M. Brander
Thomas J. Kipps
Michael Y. Choi
Mary Ann Anderson
Kathryn Humphrey
Abdullah Al Masud
John Pesko
Ruby Nandam
Ahmed Salem
Brenda Chyla
Jennifer Arzt
Amanda Jacobson
Su Young Kim
Andrew W. Roberts
Show All
Source
Cite
Save
Citations (2)
Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL
2019
Blood
Danielle M. Brander
John F. Seymour
Thomas J. Kipps
Shuo Ma
Mary Ann Anderson
Michael Y. Choi
Kathryn Humphrey
Abdullah Masud
Ruby Nandam
Amanda Jacobson
Andrew W. Roberts
Show All
Source
Cite
Save
Citations (8)
Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab
2018
Blood
Danielle M. Brander
John F. Seymour
Shuo Ma
Mary Ann Anderson
Michael Y. Choi
Thomas J. Kipps
Kathryn Humphrey
Abdullah Masud
Ruby Nandam
Su Young Kim
Maria Verdugo
Andrew W. Roberts
Show All
Source
Cite
Save
Citations (5)
1